DaVita Crecimiento futuro

Future controles de criterios 2/6

DaVita se prevé un crecimiento anual de los beneficios y los ingresos de 6.4% y 4.2% respectivamente. Se prevé que el BPA sea de grow en 13.2% al año. Se prevé que la rentabilidad de los fondos propios sea de 53.9% en 3 años.

Información clave

6.4%

Tasa de crecimiento de los beneficios

13.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	12.1%
Tasa de crecimiento de los ingresos	4.2%
Rentabilidad financiera futura	53.9%
Cobertura de analistas	Good
Última actualización	28 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16

Recent updates

DaVita Stock Is A Hold As It Expands In Latin America

Mar 18

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

Mar 13

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Mar 04

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16

DaVita could benefit from legislation that would return dialysis protection to Medicare

Aug 16

We Think DaVita (NYSE:DVA) Is Taking Some Risk With Its Debt

Aug 14

DaVita stock dips as peer Fresenius outlook weighed down by labor cost, inflation

Jul 28

DaVita: Valuation Turning Attractive

Jul 16

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Jul 13

Here's Why I Think DaVita (NYSE:DVA) Is An Interesting Stock

May 15

DaVita Offers Stability During Market Volatility

May 12

Here's Why DaVita (NYSE:DVA) Has A Meaningful Debt Burden

Apr 29

Is It Time To Consider Buying DaVita Inc. (NYSE:DVA)?

Apr 14

DaVita's Wide Moat Is Undervalued

Feb 11

Do DaVita's (NYSE:DVA) Earnings Warrant Your Attention?

Feb 11

DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet

Jan 29

When Should You Buy DaVita Inc. (NYSE:DVA)?

Jan 14

Is DaVita Inc. (NYSE:DVA) Trading At A 48% Discount?

Dec 31

Previsiones de crecimiento de beneficios e ingresos

NYSE:DVA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	13,669	821	1,384	2,275	5
12/31/2025	13,110	798	1,141	1,876	8
12/31/2024	12,567	758	1,015	1,803	6
12/31/2023	12,140	692	1,491	2,059	N/A
9/30/2023	11,911	596	1,314	1,918	N/A
6/30/2023	11,739	454	1,357	1,967	N/A
3/31/2023	11,665	500	1,077	1,705	N/A
12/31/2022	11,610	547	961	1,565	N/A
9/30/2022	11,637	680	1,152	1,751	N/A
6/30/2022	11,627	834	995	1,607	N/A
3/31/2022	11,616	903	1,479	2,099	N/A
12/31/2021	11,619	978	1,289	1,931	N/A
9/30/2021	11,580	984	1,209	1,886	N/A
6/30/2021	11,566	883	1,124	1,802	N/A
3/31/2021	11,529	791	1,108	1,773	N/A
12/31/2020	11,551	783	1,304	1,979	N/A
9/30/2020	11,544	832	1,506	2,175	N/A
6/30/2020	11,524	824	1,648	2,333	N/A
3/31/2020	11,487	816	2,112	2,834	N/A
12/31/2019	11,388	705	1,730	2,496	N/A
9/30/2019	11,311	623	1,406	2,235	N/A
6/30/2019	11,253	548	1,124	2,011	N/A
3/31/2019	11,300	551	255	1,208	N/A
12/31/2018	11,412	616	544	1,531	N/A
9/30/2018	11,378	617	621	1,592	N/A
6/30/2018	11,299	698	698	1,679	N/A
3/31/2018	11,110	652	547	1,470	N/A
12/31/2017	10,884	909	1,061	1,966	N/A
9/30/2017	7,773	1,065	N/A	1,983	N/A
6/30/2017	8,732	1,480	N/A	2,016	N/A
3/31/2017	9,747	1,382	N/A	2,391	N/A
12/31/2016	10,696	1,038	N/A	1,988	N/A
9/30/2016	14,550	716	N/A	1,918	N/A
6/30/2016	14,347	361	N/A	2,061	N/A
3/31/2016	14,065	478	N/A	1,576	N/A
12/31/2015	9,973	323	N/A	1,531	N/A
9/30/2015	13,565	484	N/A	1,051	N/A
6/30/2015	13,290	452	N/A	1,219	N/A
3/31/2015	13,027	429	N/A	1,450	N/A
12/31/2014	12,781	723	N/A	1,459	N/A
9/30/2014	12,519	727	N/A	1,884	N/A
6/30/2014	12,270	680	N/A	1,769	N/A
3/31/2014	11,971	787	N/A	1,813	N/A
12/31/2013	11,759	620	N/A	1,773	N/A
9/30/2013	11,174	564	N/A	1,619	N/A
6/30/2013	10,121	572	N/A	1,253	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. tasa de ahorro: DVA(7.5% al año) es superior a la tasa de ahorro (2.2%).

Beneficios frente mercado: DVASe prevé que los beneficios de la empresa (7.5% al año) crezcan menos que el mercado US (14.9% al año).

Beneficios de alto crecimiento: DVASe prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: DVA(3.1% al año) se prevé que crezca más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: DVASe prevé que los ingresos de la empresa (3.1% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Futura rentabilidad financiera (ROE): DVASe prevé que la Rentabilidad de los fondos propios de la empresa sea muy elevada dentro de 3 años (53.9%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

DaVita Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.4% to US$131

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Price target increased by 14% to US$120

Consensus EPS estimates increase by 13%

Price target increased by 7.3% to US$113

Price target increased by 8.1% to US$96.27

Recent updates

Davita Announces Dennis Pullin to Its Board of Directors

DaVita Stock Is A Hold As It Expands In Latin America

Chief Operating Officer of Kidney Care exercised options and sold US$3.0m worth of stock

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

CEO & Executive Director exercised options and sold US$36m worth of stock

Price target increased by 7.4% to US$131

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Chief Compliance Officer recently sold US$3.0m worth of stock

Chief Compliance Officer notifies of intention to sell stock

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Price target increased by 14% to US$120

Is DaVita (NYSE:DVA) Using Too Much Debt?

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

DaVita: Assessing After The Rally

DaVita Inc.'s (NYSE:DVA) Subdued P/E Might Signal An Opportunity

CEO & Executive Director exercised options and sold US$16m worth of stock

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 13%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

DaVita: Simple And Compelling After Sell-Off

Returns On Capital Signal Difficult Times Ahead For DaVita (NYSE:DVA)

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 19%

DaVita: Continued Economic Hurdles, Market Expectations May Be Correct

Chief Legal & Public Affairs Officer notifies of intention to sell stock

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Price target increased by 7.3% to US$113

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Takes On Some Risk With Its Use Of Debt

DaVita Inc. Announces Management Changes

DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold

Returns At DaVita (NYSE:DVA) Appear To Be Weighed Down

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

DaVita Inc. (NYSE:DVA) Shares Could Be 41% Below Their Intrinsic Value Estimate

Chief Legal & Public Affairs Officer recently sold US$1.0m worth of stock

CEO & Executive Director notifies of intention to sell stock

Price target increased by 8.1% to US$96.27

Price target increased by 8.3% to US$94.38

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

What Is DaVita Inc.'s (NYSE:DVA) Share Price Doing?

Price target increased by 8.6% to US$88.80

These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Extensively

Investors Met With Slowing Returns on Capital At DaVita (NYSE:DVA)

Director recently sold US$108k worth of stock

Are Investors Undervaluing DaVita Inc. (NYSE:DVA) By 40%?

Director exercised options and sold US$106k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 7.0% to US$86.50

DaVita HealthCare Partners Q4 2022 Earnings Preview

Moon Capital - DaVita: A Recession-Resistant Cash Generating Machine

DaVita Inc. to Report Q4, 2022 Results on Feb 22, 2023

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

Is DaVita (NYSE:DVA) A Risky Investment?

DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution

Consensus EPS estimates fall by 21%

Independent Director recently bought US$356k worth of stock

Price target decreased to US$83.57

Third quarter 2022 earnings: EPS misses analyst expectations

DaVita Q3 2022 Earnings Preview

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

DaVita Inc. to Report Q3, 2022 Results on Oct 28, 2022

DaVita: Solid Valuation And Cash Flow, Price Recovering After SCOTUS Ruling

DaVita Inc. Appoints Adam H. Schechter to Board of Directors

DaVita could benefit from legislation that would return dialysis protection to Medicare

We Think DaVita (NYSE:DVA) Is Taking Some Risk With Its Debt

Second quarter 2022 earnings: EPS exceeds analyst expectations

DaVita stock dips as peer Fresenius outlook weighed down by labor cost, inflation